mg±ùÇòÍ»ÆƹÙÍøÍøÕ¾

OAÈë¿Ú
±¨¸æµ¥ÅÌÎÊ
ÔÚÏß¿Í·þ
mg±ùÇòÍ»ÆÆ(ÖйúÓÎ)¹Ù·½ÍøÕ¾
ÐÂÎÅÖÐÐÄ
News Center
ÇÄÇēDZÔÚ”£¬×îÖÕ¿ÉÄÜÉú³¤³É“Äò¶¾Ö¢”£¡ÕâÀàÉöÔಡӦÌáǰɸ²é
Ðû²¼£º2024/03/14

ÉöÔಡÊÇÒ»Öָ߷¢¼²²¡£¬ÌìϹæÄ£ÄÚƽ¾ùÿ10¸ö³ÉÄêÈËÖоÍÓÐ1ÈË»¼ÓÐÂýÐÔÉöÔಡ£¬ÆäÒý·¢µÄéæÃüÂÊÒ»Á¬ÉÏÉý£¬Ô¤¼Æµ½2040Ä꽫»á³ÉΪµÚÎå´óËÀÒò¡£½ñÌìÊǵÚ19¸öÌìÏÂÉöÔàÈÕ£¬ÈÃÎÒÃÇÒ»Æð¹Ø×¢ÕâÀàÌØÊâµÄÉöÔ༲²¡¡­¡­


һλ32ËêµÄÄÐÊ¿ÔÚÌå¼ìʱ·¢Ã÷ÉöÔàÉÏÓÐÄÒÖס£Ëû¸æËßÌå¼ì±¨¸æ½â¶ÁÒ½Éú£¬×Ô¼ºµÄÂèÂèÊÇһλ¶àÄÒÉö²¡»¼Õß¡£ÎªÁ˽øÒ»²½Ã÷È·Õï¶Ï£¬ÔÚÒ½Éú½¨ÒéÏ£¬Ëû×öÁËÏà¹Ø»ùÒò¼ì²â¡£×ÛºÏmg±ùÇòÍ»ÆƹÙÍøÍøÕ¾³ö¾ßµÄ¼ì²â±¨¸æºÍÒÅ´«×ÉѯʦÆÊÎö£¬¼ì³öËûµÄPKD1»ùÒòÓÐÒÉËÆÖ²¡±äÒ죨NM_001009944.3 c.10796C>G p.Ser3599Ter exon36£©£¬¸Ã±äÒìÒ²ÓëÆäÏÖÔÚµÄÁÙ´²ÐÅÏ¢Ò»Ö¡£


ͨ¹ýÉÏÊö·¢Ã÷£¬×îÖÕÕï¶ÏÕâλÄÐÊ¿î¾»¼µÄÊdz£È¾É«ÌåÏÔÐÔ¶àÄÒÉö¡£ÕâÊÇÒ»ÖÖ×î³£¼ûµÄÒÅ´«ÐÔÉö²¡Ö®Ò»£¬·¢²¡ÂÊԼΪ1/1000ÇÒ»áËæ×ÅÄêËêÔöÌí¶øÔöÌí¡£Ô¼Äª50%µÄ»¼ÕßÔÚ60Ëêʱ»¼ÓÐÖÕÄ©ÆÚÉö²¡£¬Ò²¾ÍÊÇ¡°Äò¶¾Ö¢¡±¡£



ΪʲôÒÅ´«ÐÔÉö²¡ÄÑÒÔÔçÆÚ²ì¾õ£¿


ÔÚµ¼ÖÂÖÕÄ©ÆÚÉö²¡µÄÔµ¹ÊÔ­ÓÉÖУ¬ÒÅ´«ÐÔÉö²¡ÅÅÃûµÚÎ壬½ô¸úÔÚÂýÐÔÉöÑס¢ÌÇÄò²¡Éö²¡µÈÖ®ºó¡£ÓÐԼĪ10%-15%µÄÉöÔಡ»¼Õ߶¼ÊÇÓÉÓÚÒÅ´«ÒòËØ»¼²¡£¬ÌØÊâÊÇÔÚÄêÇáÈ˺ͶùͯȺÌåÖиüΪͻ³ö¡£ºÃ±È£¬ÔÚ25ËêÇ°»¼ÂýÐÔÉö²¡µÄÈËȺÖУ¬Ã¿5¸ö¾ÍÓÐ1¸öÊÇÒÅ´«ÐÔÉö²¡£»¶øÔÚÐèÒª¾ÙÐжùͯÉöÒÆÖ²µÄ²¡ÀýÖУ¬Èý³ÉÒÔÉ϶¼ÓëÒÅ´«ÓйØ¡£


ÒÅ´«ÐÔÉö²¡ÓÐ×ÅÖØ´óµÄ»ùÒòÅä¾°¡ª¡ªÏÖÔÚÒÑÖªÖ²¡»ùÒòÁè¼Ý600¸ö£¬²¢ÇÒÒÅ´«·½·¨¶àÖÖ¶àÑù£¬ÓеÄÊÇÏÔÐÔÒÅ´«£¬ÓеÄÊÇÒþÐÔÒÅ´«¡£ÕâÒâζ×Å£¬Ðí¶àÒÅ´«ÐÔÉö²¡ÔÚ³õÆڽ׶ÎÍùÍùÖ¢×´²»ÏÔ×Å»òÕßÓëÆäËûÀàÐÍÉö²¡ÏàËÆ£¬²»Ò×±»Ê¶±ð³öÀ´£¬ÉõÖÁÓÐʱֱµ½²¡ÇéÉú³¤µ½Éö¹¦Ð§Ë¥½ßµÄÌïµØ²Å±»È·Õï¡£


±ðµÄ£¬ÉÐÓÐÐí¶à¹ýʧµÄ¿´·¨Ò²ÔÚÎóµ¼×Å»¼Õߣº¡°ÒÅ´«ÐÔÉö²¡¾ÍÊÇÏÈÌìÐÔÉö²¡£¬ÎÒ¶¼¼¸Ê®ËêÁ˲ŵõÄÉö²¡£¬Ò»¶¨²»ÊÇÒÅ´«²¡¡£¡±¡°âïÊѶ¼Ã»²¡£¬ÎÒÒ»¶¨²»ÊÇÒÅ´«²¡¡£¡±ÊÂʵÉÏ£¬ÒÅ´«²¡¼È¿ÉÒÔÊÇÓ¤Ó׶ùʱÆÚ·¢²¡£¬Ò²»áÍíÖÁ¼¸Ê®ËêÉõÖÁÍíÄêʱ²ÅÊ×´ÎÕ¹ÏÖ²¡Ö¢¡£ÒÔÊÇ£¬ÏÖÔÚ¿´ÆðÀ´¿µ½¡µÄÈË£¬Ò²ÓпÉÄÜЯ´øÖ²¡»ùÒò¶ø²»×ÔÖª£¬²¢½«Õâ¸öΣº¦ÇÄÎÞÉùÏ¢µØ´«¸øÏÂÒ»´ú¡£



»ùÒò¼ì²âÖúÁ¦ÒÅ´«ÐÔÉö²¡ÔçÕï¶Ï


»ùÒò¼ì²âÊÖÒÕͨ¹ý¼ì²âÈËÌåDNAÖеıäÒ죬Äܹ»×¼È·Ê¶±ðÓëÒÅ´«ÐÔÉö²¡Ïà¹ØµÄÌض¨»ùÒòÍ»±ä£¬ÊµÏÖ¼²²¡µÄÔçÆÚ¡¢¾«×¼Õï¶Ï£¬¿ÉÒÔÖ»¹Ü×èÖ¹½öÒÀÀµÁÙ´²Ö¢×´µ¼ÖµÄÎóÕï»òÑÓ³ÙÕï¶Ï¡£


ÄÄЩÉö²¡»¼Õß½¨Òé×ö»ùÒò¼ì²â£¿


1.ÁÙ´²ÌåÏÖÀàËÆÒÅ´«ÐÔ¼²²¡£»

2.ÓÐÃ÷È·µÄÒÅ´«ÇãÏò£»

3.ÓмÒ×åÊ·£»

4.ͨÀýµÄÁÙ´²Á÷³ÌÄÑÒÔÈ·Õ

5.ÔçÆÚÕï¶ÏÓÐÖúÓÚÔ¤·ÀÐÔ¸ÉÔ¤£»

6.ÌØÊâµÄµØÇøºÍÖÖ×å¡£


¼ò¶øÑÔÖ®£¬¹ØÓÚÄÇЩÔçÆÚ·¢²¡¡¢Õï¶Ï²»Ã÷¡¢ÖÎÁÆЧ¹û²»¼Ñ¡¢ÏÓÒɾßÓÐÒÅ´«ÐÔ×Ó»òÓмÒ×åÉö²¡Ê·µÄ»¼Õߣ¬¶¼½¨Òé˼Á¿¾ÙÐлùÒò¼ì²â¡£



»ùÒò¼ì²âÔÚÒÅ´«ÐÔÉö²¡ÕïÁÆÖеÄ×÷ÓÃ


1.ÅжÏÏêϸÀàÐÍ£¬Ö¸µ¼ÖÎÁÆÆ«Ïò£¬ÅжÏÔ¤ºó¡£

  • ׼ȷʶ±ðÒÅ´«ÐÔÉö²¡µÄÀàÐÍ£¬Îª»¼ÕßÌṩÕë¶ÔÐÔµÄÖÎÁƼƻ®¡£²¿·ÖÒÅ´«ÐÔÉö²¡ÈçÊÊÓø¨Ã¸Q10¡¢Íз¥ÆÕ̹µÈÒ©ÎïÖÎÁƵÄÇéÐΣ¬Í¨¹ý¼ì²â¿ÉÃ÷È·ÓÃÒ©Ñ¡Ôñ£»Í¬Ê±×èÖ¹ÎÞЧÖÎÁÆ£¬¼õÇá¾­¼Ã¼ç¸ººÍÒ©Î︱×÷Óá£

  • ×ÊÖúÕ¹Íû¼²²¡Éú³¤Àú³Ì£¬ÊÊʱÆô¶¯¸ÉÔ¤²½·¥£¬×ÊÖúÔ¤¹ÀÉöË¥½ßµÄ±¬·¢Ê±¼ä£¬ÒÔ±ãʵʱÖƶ©¸öÐÔ»¯Ò½ÁÆÕ½ÂÔ¡£

  • ÓÐÖúÓÚÒ½Éú¸üºÃµØÆÀ¹ÀÉöÒÆÖ²ÊÖÊõµÄÀÖ³ÉÂʼ°ºóÐø¹ÜÀí¡£


2.ɸ²é¼ÒÍ¥¸ßΣ³ÉÔ±£¬Ö¸µ¼ÓÅÉúÓÅÓý¡£

  • ¿ÉÕ¹ÏÖ¼Ò×åÖÐÆäËû³ÉÔ±µÄ»¼²¡Î£º¦¡£

  • ¹ØÓÚÓÐÉúÓýÍýÏëµÄ¼ÒÍ¥À´Ëµ£¬¿Éͨ¹ý»ùÒò¼ì²â¾ÙÐÐÅßÌ¥Ö²ÈëÇ°»ò²úÇ°ÒÅ´«É¸²é£¬ÌáÇ°µÃÖª×ÓÅ®ÊÇ·ñЯ´øÖ²¡»ùÒò£¬ÊµÏÖÓÅÉúÓÅÓý¡£



»ùÒò¼ì²âÔõô×ö£¿


ÉöÔàÏà¹Ø»ùÒò¼ì²âͨ³£Í¨¹ý¼òÆӵijéѪÀ´»ñÈ¡Ñù±¾£¬ÊܼìÈËÎÞÐèÌØÊâ×¼±¸£¬¿Õ¸¹¡¢ÓÃÒ©µÈ¾ù²»Ó°ÏìÑù±¾¡£µ«ÎªÁ˸üºÃµØÃ÷È·Õï¶Ï£¬ËͼìÕßÐèÌṩÏ꾡µÄ²¡Ê·ºÍÁÙ´²×ÊÁÏ¡£mg±ùÇòÍ»ÆƹÙÍøÍøÕ¾¿ÉÌṩÒÅ´«ÐÔÉö²¡Õï¶ÏÕûÌå½â¾ö¼Æ»®£¬²¢ÓÉרҵµÄÒÅ´«×ÉѯʦÍŶÓÌṩ±¨¸æ½â¶Á·þÎñ¡£

ÏîÄ¿±í.jpg

mg±ùÇòÍ»ÆƹÙÍøÍøÕ¾ÉöÔಡÏà¹Ø»ùÒò¼ì²âÏîÄ¿


mg±ùÇòÍ»ÆƹÙÍøÍøÕ¾³Ð¼Ì¡°ÁÙ´²±íÐÍ+¾­¼Ã¸ßЧ¡±µÄ»ùÒòÕï¶ÏÀíÄÔÚÌá¸ßÒÅ´«ÐÔÉö²¡¼ì²âˮƽµÄͬʱ£¬³ä·ÖÍŽỼÕßµÄÁÙ´²ÌåÏÖÌØÕ÷¼°ÒÅ´«Åä¾°ÐÅÏ¢£¬ÖúÁ¦Ò½Éú¸ü׼ȷµØÕï¶Ï¼²²¡ÀàÐͺÍÕ¹Íû¼²²¡Éú³¤Ç÷ÊÆ£¬´Ó¶øΪ»¼ÕßÌṩÕë¶ÔÐÔÖÎÁÆ£¬ÓÐÓüõÇá¼²²¡ÕïÁÆÀú³ÌÖеľ­¼Ã¼ç¸º¡£


³ýÁËͨ¹ý»ùÒò¼ì²âÖúÁ¦ÒÅ´«ÐÔÉö²¡ÔçÕï¶Ï£¬mg±ùÇòÍ»ÆƹÙÍøÍøÕ¾ÔçÒѽ¨ÉèÉöÔಡ¼ì²âÖÐÐÄ£¬ÒÔ±ê×¼»¯ºÍ¹æ·¶»¯µÄÉö»î¼ì²¡Àí¼ì²é¼°±¨¸æϵͳΪ»ù´¡£¬Á¢ÒìÈÚºÏÊý×Ö»¯²¡ÀíÊÖÒÕºÍÍøÂçƽ̨ÓÅÊÆ£¬ÎªÁÙ´²Õï¶Ï¡¢ÁÙ´²ÊÔÑéÓë¿ÆÑС¢ÐÂÖÎÁưеãµÄÑ°ÕÒµÈÌṩ¼ì²â·þÎñ£¬ÖúÁ¦ÁÙ´²Öƶ©ÖÖÖÖÉöÔ༲²¡µÄ¸öÌ廯ÖÎÁƼƻ®¡£


²Î¿¼ÎÄÏ×


[1]M¨¹ller RU, Messchendorp AL, Birn H, et al. An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International. Nephrol Dial Transplant. 2022 Apr 25;37(5):825-839.

[2]ÐìµÂ³¬,÷³¤ÁÖ. ¶àÄÒÉö²¡µÄÁÙ´²Êµ¼ùÖ¸ÄÏ[J]. ÖлªÒ½Ñ§ÒÅ´«Ñ§ÔÓÖ¾, 2020(3): 277-283.

[3]Íз¥ÆÕ̹ÖÎÁÆ¿ìËÙÏ£ÍûÐͳ£È¾É«ÌåÏÔÐÔ¶àÄÒÉö²¡×¨¼Ò×é. Íз¥ÆÕ̹ÖÎÁÆ¿ìËÙÏ£ÍûÐͳ£È¾É«ÌåÏÔÐÔ¶àÄÒÉö²¡Öйúר¼Ò¹²Ê¶[J]. ÖлªÉöÔಡÔÓÖ¾, 2022, 38(7): 644-652.


ÍøÕ¾µØͼ